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Abstract
Epidermal growth factor receptor (EGFR) and androgen receptor (AR) pathways play pivotal roles in prostate cancer
progression. Therefore, agents with dual-targeting ability may have important therapeutic potential. Decorin, a
proteoglycan present in the tumor microenvironment, is known to regulate matrix assembly, growth factor binding,
and receptor tyrosine kinase activity. Here, we show that in prostate-specific PtenP−/− mice, a genetically defined,
immune-competent mouse model of prostate cancer, systemic delivery of decorin inhibits tumor progression by
targeting cell proliferation and survival pathways. Moreover, in human prostate cancer cells, we show that decorin
specifically inhibits EGFR and AR phosphorylation and cross talk between these pathways. This prevents AR nuclear
translocation and inhibits the production of prostate specific antigen. Further, the phosphatidylinositol-3 kinase
(PI3K)/Akt cell survival pathway is suppressed leading to tumor cell apoptosis. Those findings highlight the effective-
ness of decorin in the presence of a powerful genetic cancer risk and implicate decorin as a potential new agent for
prostate cancer therapy by targeting EGFR/AR-PI3K-Akt pathways.
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Introduction
Prostate cancer is the most common form of cancer and the second
leading cause of cancer-related death among men in the United
States. Its development in humans proceeds through multiple de-
fined steps: prostatic intraepithelial neoplasia, prostate cancer in situ,
invasive, and hormone-dependent or -independent metastatic cancer.
Despite the initial efficacy of androgen deprivation therapy, tumor
cells eventually relapse into hormone-refractory prostate cancer [1].
The therapeutically critical switch of prostate cancer to androgen
independence and distant metastasis requires an interactive micro-
environment to facilitate survival and proliferation of malignant cells
[2]. Therefore, identifying signaling events emanating from the micro-
environment may lead to novel therapeutic targets for prostate cancer.
Decorin is a small leucine-rich proteoglycan secreted mainly by cells
of mesenchymal origin. It is an important regulator of collagen fibrillo-
genesis and extracellular matrix assembly, as well as cell attachment and
migration [3], and is involved in physiological processes including in-
flammatory responses [4] and wound healing [5]. Its presence in the
tumormicroenvironment is proposed to reflect an attempt by the stroma
to wall off the tumor [6,7]. Importantly, decorin has been shown to exert
powerful growth-inhibitory properties through effects on tyrosine kinase
signaling [8,9]. It is markedly upregulated during quiescence in fibro-
blasts and vascular smooth muscle cells [10,11], but its expression is
suppressed or totally abrogated in a variety of tumors of epithelial origin
such as colon, pancreas, and breast [12]. A number of human cancer cell
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lines do not express decorin [13,14], and forced expression of decorin in
cancer cell lines in vitro caused a severe cytostatic effect. Known mecha-
nisms for cell growth inhibition by decorin include up-regulation of
the cell cycle inhibitor p21 [14–16] and p27 [17], down-regulation of
epidermal growth factor receptor (EGFR) [9,18], blockade of the trans-
forming growth factor β signaling pathway [19,20], and suppression of
tumor cell production of angiogenic factors such as vascular endothelial
growth factor [21,22].
In mice, targeted disruption of both decorin and P53 genes resulted
in the acceleration of malignant lymphomas [23]. More recently, a
report showed that 30% of decorin-deficient mice developed sponta-
neous intestinal tumors [24]. Furthermore, recombinant humandecorin
has been shown to inhibit the growth of tumor xenografts including
those derived from breast, colon, and squamous carcinoma [25], lung
and liver carcinoma [26], and gliomas [27]. However, the effects of
systemically delivered decorin have not previously been studied in an
immune-competent animal model with a defined genetic cancer risk
or in any studies in prostate cancer.
Because decorin was shown to be expressed in high-grade human
prostatic intraepithelial neoplasia but not in prostate cancer [28], we
hypothesized that decorin may function in a cancer-inhibitory role in
the prostate. To demonstrate such a role, we used prostate-specific Pten
(phosphatase and tensin homolog deleted on chromosome 10) knock-
out mice, an immune-competent, orthotopic model of prostate cancer,
and studied the effects of exogenous decorin on tumor growth. In this
model and in cultured human prostate cancer cell lines, decorin inhib-
ited growth and induced apoptosis. It did so by the inhibition of the
EGFR, androgen receptor (AR), and phosphatidylinositol-3 kinase
(PI3K)/Akt signal pathways.
Materials and Methods
Cell Lines and Reagents
DU145, LNCaP, and PC3 cells were purchased from the American
Type Culture Collection (Manassas, VA) and maintained in Eagle’s
minimum essential medium with Earle’s salts containing 10% fetal
bovine serum (FBS), 1.5 g/L NaHCO3, and 1% L-glutamine (DU145
cells); RPMI-1640 medium plus 10% FBS, 1.5 g/L sodium bicarbonate,
4.5 g/L glucose, 10mMHEPES, and110mg/L sodiumpyruvate (LNCaP
cells); or advanced Dulbecco’s modified Eagle medium (DMEM) con-
taining 1% FBS and 1% L-glutamine (PC3 cells). CellTiter 96 AQueous
One Solution Cell Proliferation Assay and Caspase–Glo 3/7 Assay were
purchased from Promega (Madison, WI). AG1478 was purchased from
Invitrogen Corporation (Carlsbad, CA), and bicalutamide was from
Toronto Research Chemicals, Inc. (North York, Ontario, Canada). [3H]-
Thymidine was purchased from PerkinElmer Life and Analytical Sci-
ences (Boston, MA). Advanced DMEM, Eagle’s minimum essential
medium with Earle’s salts, and FBS were purchased from Invitrogen,
and HyQ RPMI 1640 medium was purchased from Hyclone (Logan,
UT). Bovine anti-Akt, anti–phospho-Akt (Ser 473), anti-PI3 kinase
110α, anti-AR, anti-EGFR, anti–phospho-EGFR (Tyr 1068), anti-PARP,
anti–cyclic adenosine monophosphate response element binding protein,
and anti–glyceraldehyde-3-phosphate dehydrogenase were purchased
from Cell Signaling Technology (Danvers, MA). Anti-AR (N-20) was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-PSA
and anti–phospho-AR (Ser 213/210) were purchased from Imgenex
(Fremont, CA). Anti–β-actin antibody, wortmannin, and dihydrotestos-
terone (DHT) was purchased from Sigma-Aldrich Company Ltd.
(Allentown, PA). Horseradish peroxidase–conjugated secondary anti-
bodies against mouse and rabbit were purchased from Imgenex and
Cell Signaling Technology, respectively.
Expression and Purification of Decorin and Biglycan
Core Protein
Recombinant decorin and biglycan were expressed as a polyhistidine
fusion protein in 293-EBNA cells using a CelliGen Plus Bioreactor
(New Brunswick Scientific, Edison, NJ) as described previously
[29,30]. In brief, cells were grown in DMEM containing 5% FBS to
achieve the desired cell number. Media were then changed to serum-
free conditioned media collected every 48 hours. Initial purification of
decorin and biglycan proteoglycan and core protein was performed by
passing 293 conditioned media over a nickel-chelating column followed
by elution with a gradient of 0 to 250 mM imidazole in 20 mM
Tris-HCl, 500 mM NaCl, 0.2% 3-[(3-cholamidopropyl)dimethylamino]-
1-propanesulfonate, pH 8.0. Core protein was then separated from
proteoglycan using anion-exchange chromatography on Q-Sepharose
(Amersham Biosciences, Uppsala, Sweden).
Prostate-Specific Pten Knockout Mice
As previously described [31–33], prostate-specific Pten knockout
mice were generated by crossing Pten loxP/loxP mice with mice of
the ARR2Probasin-Cre transgenic line PB-cre4, wherein the Cre recom-
binase is under the control of a modified rat prostate-specific probasin
promoter. B6.129S4-Gt (ROSA) 26Sortm1Sor/J mice, which have a
floxed lacZ gene targeted to theROSA26 locus, whose expression depends
onCre activity, were purchased from the Jackson Laboratory (BarHarbor,
ME). For simplicity, PtenloxP/loxPPB-cre4−/− and PtenloxP/+PB-cre4−/− are
referred to as PtenP+/+ and PtenloxP/loxP PB-cre4T/− as PtenP−/−. After
weaning, PtenP−/− mice were injected intraperitoneally on alternate days
with decorin (10 mg/kg body weight), biglycan (10 mg/kg body
weight), or saline. This concentration was based on that shown to in-
hibit the growth of squamous cell carcinoma xenografts [29]. After
the 12-week treatment, individual prostate lobes (anterior, dorsolateral,
and ventral) were dissected and separated under a stereomicroscope.
For later use for protein and RNA preparation, tissues were snap-frozen
in liquid nitrogen and stored at −70°C until analysis. Prostates used
for immunohistochemistry analysis were fixed in 10% buffered for-
malin. Histopathologic evaluation of mouse prostate tissues was per-
formed by board-certified veterinary pathologists with a double-blind
method. The protocol was approved by our institutional animal care
and use committee.
Immunohistochemical Analysis
Mouse prostate tumor tissues were fixed in buffered formalin and
embedded in paraffin. For all immunohistochemical staining (Ki-67
and caspase 3), at least two sections of each prostate lobe were assessed.
Pretreated sections were incubated with rabbit monoclonal anti–Ki-67
(Lab Vision/NeoMarkers, Fremont, CA) or rabbit polyclonal anti-
cleaved caspase 3 (Cell Signaling Technology) followed by a biotinylated
antirabbit secondary antibody and streptavidin alkaline phosphatase
(Super Sensitive Link-Label IHC Detection Systems; Bio-Genex, San
Ramon, CA), visualized with Vector Red Substrate (SK-5100; Vector
Laboratories, Burlingame, CA), and counterstained with hematoxylin.
Negative control slides were performed without primary antibody.
Control slides known to be positive for each antibody were incorpo-
rated. The total number of epithelial cells was enumerated in all glands
and processed using Image-Pro Plus 5.1 software (Media Cybernetics,
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Bethesda, MD). Ki-67 and caspase 3 staining was quantified by count-
ing the number of positively stained nuclei among 100 cells on grids in
three randomly chosen fields from different sections.
Cell Proliferation Assay
Cell proliferation was measured with the use of a CellTiter 96
AQueous Non-Radioactive Cell Proliferation Assay (Promega). Briefly,
prostate cancer cells were plated in 96-well plates at a density of 2 × 103
per well in 100 μl of medium. After attachment, cells were treated with
decorin or biglycan at varying concentrations and times and in the
presence or absence of 2 μM AG1478 or 0.5 μM bicalutamide. After
treatment, 20 μl of combined 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner salt
(MTS)/phenazine methosulfate solution was then added and incubated
for 2 hours at 37°C. The absorbance of each well at 490 nm was
measured using an ELISA plate reader. Data represent the average
absorbance of three wells, and error bars represent SDs.
DNA Synthesis
Cells were plated in 24-well plates at density of 2 × 103 per well.
After 24 hours, culture media were supplemented with 5 μCi/ml
[3H]-thymidine, and cells were incubated with decorin or biglycan
(0.4, 1, and 2 μM) for 24 hours. Cells were then washed with
balanced salt solution (BSS) and trypsinized (200 μl of 0.05% trypsin
for 5 minutes), then 400 μl of BSS was added. Wells were rinsed with
400 μl of BSS and pooled with trypsin fluids. One milliliter of ice-cold
10% trichloroacetic acid and 50 μl of serum were added, and samples
were vortexed then held on ice for 1 hour and centrifuged at 2000 rpm
for 10 minutes at 4°C. Supernatants were removed, and pellets were
washed five times with 2 ml of ice-cold 5% trichloroacetic acid. Pellets
were dissolved in 500 μl of 0.5N NaOH. [3H]-Thymidine incorpora-
tion was determined by liquid scintillation counting.
Cytosolic and Nuclear Protein Extracts from LNCaP Cells
LNCaP cells were seeded in 100-mmdishes at a density of 2 × 106 cells
per dish. After attachment, cells were treated with decorin (2 μM)
or biglycan (2 μM) for 24 hours. Cells were then washed three
times with ice-cold PBS and rinsed with 1× hypotonic buffer contain-
ing 20 mM HEPES (pH 7.9), 1 mM EDTA, 1 mM EGTA, 1 mM
DL-dithiothreitol, and 0.5 mMphenylmethyl sulfonyl fluoride (PMSF).
Cells were lysed with 200 μl of 1× hypotonic buffer containing 0.2%
NP-40. Cell lysates were centrifuged for 20 seconds at 15,000 rpm at
4°C. Supernatants (cytosolic extracts) were transferred to a new tube
and kept at −20°C. The pellet was resuspended in 50 μl of 1× high salt
buffer (420 mMNaCl, 20 mMHEPES, pH 7.9, 1 mMEDTA, 1 mM
EGTA, 20% glycerol, 1 mM DL-dithiothreitol, 0.5 mM PMSF) and
incubated on ice for 30 minutes. After centrifugation at 12,000 rpm
for 20 minutes at 4°C, the supernatant was harvested as the nuclear
protein extract and stored at −80°C. Protein concentration was deter-
mined with a Lowry protein assay. Western blot assay was performed
using antibodies recognizing the cytosolic protein, glyceraldehyde-3-
phosphate dehydrogenase, or the nuclear protein, cyclic adenosine
monophosphate response element binding protein.
Western Blot Assay
Prostate tissues were homogenized and cells were lysed in ice-cold
lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100,
and 0.1 mg/ml PMSF) with 1× proteinase and 1× phosphatase inhibi-
tors (Roche Applied Science, Indianapolis, IN). For the analysis of
decorin core protein, lysis solution was dialyzed against 100 mM Tris,
30 mM sodium acetate, pH 8.0 for 24 hours at 4°C, and then di-
gested by chondroitinase ABC at 37°C overnight. Protein extracts
were electrophoresed by 12.5% SDS-PAGE and transferred to a nitro-
cellulose membrane. After blocking with 5% nonfat dry milk, the
membrane was washed three times with TBS/Tween-20 and incubated
with the primary antibody diluted in 3% BSA at 4°C overnight. The
blot was washed in TBS/Tween-20 and incubated for 1 hour with a
horseradish peroxidase–conjugated secondary antibody diluted at 1:
2000 for goat antimouse and goat antirabbit. The signal was detected
using the chemiluminescent detection system (Pierce, Rockford, IL).
Immunofluorescence Analysis for AR
LNCaP cells were plated on coverslips in wells of a 24-well plate
containing RPMI-1640 medium with 10% FBS. Cells were treated
with 2 μM decorin or 2 μM biglycan for 24 hours followed by incu-
bation with and without 1 nM DHT for 2 hours. Cells were then
fixed with 10% formalin for 30 minutes. Coverslips were rinsed with
PBS and permeabilized with 0.2% Triton X-100 for 30 minutes, then
washed three times with PBS and incubated with anti-AR antibody
(1:100; Santa Cruz Biotechnology) for 1 hour. After washing with
PBS, cells were incubated with Alexa Fluor 488 goat antirabbit immu-
noglobulin G (Invitrogen) for 1 hour along with 4′,-6-diamidino-2-
phenylindole (30 nM) for 15 minutes in the dark and washed three
times with PBS. Cell images were captured under microscope with a
digital camera and processed using Image-Pro Plus 5.1 software.
EGFR Gene Silencing by Small Interfering RNA
Two small interfering RNA (siRNA) specific for human EGFR
gene was purchased fromQiagen (Hs_EGFR_10HPValidated siRNA,
Cat. No. SI02660140 and Hs_EGFR_12 HP Validated siRNA,
Cat. No. SI02663983; Germantown, MD). For knockdown of EGFR
in LNCaP cells, the individual siRNA was tested for EGFR and
phospho-EGFR knockdown by Western blot assay. The most effective
single siRNA (SI02663983) was used for further experiments. LNCaP
cells were plated in a six-well plate at 2.0 × 105 cells and were trans-
fected with siRNA and Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s protocol. Control cells were transfected with a
negative control siRNA. At 6 hours after transfection, each well was
supplemented with growth medium containing 1% FBS for 24 hours.
Cells were treated with decorin (2 μM) for 48 hours followed by EGF
(100 ng/ml) for 15 minutes and were harvested to measure the amount
of AR and AR phosphorylation.
Caspase 3 Activity Measurement
PC3 and LNCaP cells (103 cells per well) were cultured in 96-well
plates for 24 hours then treated for 48 hours with decorin (2 μM)
in the presence or absence of pretreatment with AG1478 (2 μM,
30 minutes), bicalutamide (0.5 μM for 90 minutes), or a combination
of both. Caspase 3 activity was measured with the Caspase–Glo 3/7
Assay in which 30μl of Caspase–Glo 3/7 reagent was added to each well
and incubated for 1 hour at room temperature. Luminescence was mea-
sured with a Reporter Microplate luminometer (Turner BioSystems,
Sunnyvale, CA).
Statistical Analysis
Data are expressed as the mean ± SD. Statistical analysis was per-
formed using one-way analysis of variance. P values <.05 were consid-
ered statistically significant.
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Results
Endogenous Decorin Expression Was Reduced, and an
Exogenous Recombinant Decorin Inhibits Prostate
Cancer Growth
Conditional deletion of the Pten gene in mouse prostate epithelium
results in hyperplasia at 4 weeks of age and progression through carci-
noma in situ to invasive adenocarcinoma by 16 weeks [34]. We have
observed that endogenous decorin core protein levels in Pten null pros-
tate glands are markedly lower compared with glands from PtenP+/+
mice (data not shown). To determine the effect of systemic delivery
of decorin on prostate cancer development, 4-week-old male PtenP−/−
mice were randomized into three treatment groups to receive alternate-
day intraperitoneal injections of saline, human recombinant decorin, or
human recombinant biglycan (a related small leucine-rich proteoglycan,
as negative control). At 12 weeks, mice were necropsied, prostate glands
were weighed, and pathologic changes were evaluated. Decorin treat-
ment resulted in a significant decrease in tumor weight compared with
control groups (Figure 1A). Pathologic evaluation confirmed that histo-
logic progression of tumors was retarded in decorin-treated animals,
which generally developed prostate lesions with intermediate histo-
pathology, carcinoma in situ, whereas mice injected with saline had a
higher percentage of invasive adenocarcinoma (Figure 1B). Further-
more, cell proliferation as measured by Ki-67 immunostaining was
Figure 1. Exogenous decorin core protein inhibited the growth of prostate tumor in PtenP−/−mice. (A) Mice (n = 5 mice each group) were
treated with decorin (10 mg/kg body weight), biglycan (10 mg/kg body weight), or saline through intraperitoneal injection for 12 weeks after
weaning. The anterior (AP), dorsolateral (DL), and ventral (VP) prostate lobes were weighed and calculated as milligrams per 25-g body
weight. Data were expressed as means ± SD and analyzed by one-way analysis of variance. Values with different letters are significantly
different (P < .05). (B) Prostate grading of 10 PtenP−/− mice treated with either decorin (10 mg/kg body weight) or saline (control) was
analyzed in AP, DL, and VP lobes using a double-blind method. When complex histologic diagnosis was found, the most advanced type
was indicated. cis indicates carcinoma in situ; hyper, hyperplasia; inv. ca, invasive adenocarcinoma. (C) PtenP−/−mice treated with decorin
(10 mg/kg body weight), biglycan (10 mg/kg body weight), or saline were randomly selected to analyze cell proliferation in prostate glands
using immunohistochemistry with anti–Ki-67 antibody. Photos are representative of results obtained from three mice per group. Scale bar,
100 μm. Histograms at bottom show quantification of Ki-67–positive cells. (D) PtenP−/−mice treated with decorin (10 mg/kg body weight),
biglycan (10 mg/kg body weight), or saline were randomly selected to measure apoptosis in prostate glands using immunohistochemistry
with anti–cleaved caspase 3 antibodies. Photos are representative of results obtained from three mice per group. Scale bar, 100 μm. Histo-
grams at the bottom show quantification of cleaved caspase 3–positive cells.
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dramatically reduced in all prostate lobes of decorin-treated animals
(Figure 1C), and apoptosis as measured by cleaved caspase 3 immuno-
staining was significantly higher (Figure 1D). All of these measures were
consistent in supporting a tumor-inhibitory role in vivo for systemically
delivered decorin.
Decorin Inhibited the Growth of Human Prostate Cancer Cells
To test if decorin had a growth-inhibitory effect on human prostate
cancer cells, androgen-independent (PC3 and DU145) and androgen-
dependent (LNCaP) cell lines were treated with decorin. A signifi-
cant decrease in proliferation of all three cell lines was observed in a
dose-dependent manner after 1 to 4 days of treatment with decorin
(Figure 2A). Decorin (1 and 2 μM) also inhibited DNA synthesis as
measured by [3H]-thymidine incorporation, within as little as 24 hours
in PC3, LNCaP, and DU145 cells (Figure 2B). The effect was specific
for decorin because biglycan had no significant effect on prolifera-
tion or DNA synthesis of the prostate cancer cells (Figure 2, A, insets,
and B).
Decorin Downregulates EGFR
Transmission of extracellular signals often starts with binding of a
growth factor to surface receptors. Previous studies have found that
decorin is a ligand of EGFR that attenuates rather than triggers EGFR
signaling in some epithelial-derived tumor cells [9,18,35]. Therefore,
we measured EGFR expression by Western blot to determine the role
of EGFR signaling in decorin-induced growth inhibition in prostate
cancer. Figure 3A shows that systemic decorin treatment reduced total
EGFR expression and rendered the phosphorylated EGFR undetect-
able in all prostate lobes of PtenP−/−mice. In human cell lines, our study
showed that the basal level of EGFR expression was 1.6- and 1.3-fold
higher in PC3 and DU145 cells, respectively, than in LNCaP cells
(Figure 3B). Decorin decreased total EGFR after 5 to 10 minutes of
exposure (Figure 3C), but the reduced total EGFR was subsequently
returned to normal level (Figure 3B). Decorin dramatically reduced
EGFR phosphorylation suggesting deactivation of EGFR (Figure 3,
B and C). The dynamic effect of decorin on total EGFR in vitro (within
the 48-hour exposure) indicates that a short exposure (<20 minutes)
to decorin causes a reversible down-regulation of total EGFR, as was
Figure 2. Decorin inhibited the growth of human prostate cancer cells. (A) PC3, DU145, and LNCaP cells were treatedwith decorin (0, 0.4, 1,
and 2 μM) or biglycan (2 μM, insets), and cell number wasmeasured as absorbance at 490 nm at the indicated times usingMTS assay. Data
are expressed as fold increases relative to pretreatment (0 time) for each treatment. *P < .05 or **P < .01, compared with control at the
same observed time point. (B) PC3, DU145, and LNCaP cells were treated with decorin or biglycan at 0.2, 1, and 2 μM for 24 hours. DNA
synthesis was measured by [3H]-thymidine incorporation. Values shown are thymidine incorporation as a percent of control (no decorin) and
represent mean ± SD (n = 3). Values with different letters are significantly different (P < .05).
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observed in A431 human squamous carcinoma cells [29]. It is possible
that changes in the cellular composition of the tumor are reflected in
our in vivo measures. At the very least, these data imply that decorin
prevents EGFR phosphorylation in vivo as well as in vitro.
We also examined EGFR phosphorylation in response to EGF.
LNCaP cells were treated with decorin and/or Tyrphostin AG1478
(specific inhibitor of the EGFR tyrosine kinase) and/or EGF for 10min-
utes. EGF-induced EGFR phosphorylation (Figure 3D) and cell pro-
liferation (Figure 3E ) were attenuated by decorin or AG1478. EGF
reduced total EGFR, and decorin did not block the effect (Figure 3D).
In addition, AG1478 partially reversed the inhibitory effect of decorin
on cell proliferation in LNCaP cells (Figure 3E) and totally reversed it
in PC3 cells and DU145 cells (Figure 3F). An equal amount of recom-
binant human biglycan was essentially ineffective, indicating that the
effects on EGFR phosphorylation and cell proliferation were specific
to decorin (Figure 3, B and F).
Decorin Inhibits AR Expression and Nuclear Translocation
Androgen is known to modulate the development of human pros-
tate cancer by binding to AR. In addition, AR and Pten coexpression
is associated with the response to hormonal treatment in androgen-
dependent prostate cancer [36] and androgen ablation therapy has
been shown to prolong survival in Pten null mice [34]. We investigated
the ability of decorin to regulate AR activity in prostate tissue of
PtenP−/− mice and human prostate cancer cells. As shown by Western
blot analysis in Figure 4A, decorin markedly inhibited the expression
and phosphorylation of AR in all prostate lobes of PtenP−/− mice. In
human prostate cancer cells, neither nonphosphorylated nor phos-
phorylated AR was detected in androgen-independent PC3 and
DU145 lines, but in androgen-dependent LNCaP cells, decorin caused
a dose-dependent inhibition of AR expression and phosphoryla-
tion, whereas biglycan was ineffective (Figure 4B). The expression of
prostate-specific antigen (PSA) was similarly inhibited in LNCaP cells
by decorin (Figure 4B). Immunofluorescent staining of LNCaP cells
showed that the AR activating ligand, DHT, enhanced AR nuclear
translocation and that this translocation was blocked by decorin (Fig-
ure 4C ). This finding was supported by Western blot analysis of iso-
lated nuclear and cytosolic fractions that showed markedly decreased
AR in the nuclear fraction of cells treated with decorin (Figure 4D).
Treatment of the cells with biglycan (2 μM) did not impact AR proteins
Figure 3. Decorin inhibited EGFR and EGFR phosphorylation in prostate of PtenP−/− mice and human prostate cancer cells. (A) Prostate
tissues from AP, DL, and VP of PtenP−/−mice treated with decorin or saline (n= 2 mice each group) were homogenized with lysis buffer
containing protease and phosphatase inhibitors. Protein extracts was analyzed byWestern blots for EGFR, EGFR phosphorylation (Tyr 1068),
and β-actin. (B) Cells were treated with decorin (1 and 2 μM) or biglycan (2 μM) for 48 hours. The cells were lysed, and EGFR and its phos-
phorylation (p-EGFR, Tyr 1068) weremeasured byWestern blot analysis of 20-μg per well protein aliquots. Data shown are representative of
three experiments with similar results. (C) PC3 cells were treated with decorin (2 μM) for 5, 10, or 20 minutes. Total proteins were used
to measure EGFR and EGFR phosphorylation (Tyr 1068) byWestern blot assay. Results are representative of two independent experiments.
(D) LNCaP cells were treated with decorin (2 μM), AG1478 (2 μM), and/or EGF (100 ng/ml) for 10 minutes. Total proteins were analyzed by
Western blot analysis with anti–phospho-EGFR (Tyr 1068) or anti–total EGFR antibodies. Results are representative of two independent
experiments. (E) Cells were exposed to decorin (2 μM), biglycan (2 μM), AG1478 (2 μM), and/or EGF (100 ng/ml) for 48 hours. Cell number
was measured by MTS. Values representing the mean ± SD (n = 4) with different letters indicate significant differences (P < .05). (F) PC3
and DU145 cells were exposed to EGFR kinase inhibitor, AG1478 (2 μM, pretreated for 30 minutes), decorin (2 μM), or biglycan (2 μM).
Cell number was measured by MTS after 72 hours. Values representing the mean ± SD (n = 4) with different letters indicate significant
differences (P < .05).
Neoplasia Vol. 11, No. 10, 2009 Decorin and Prostate Cancer Hu et al. 1047
or AR translocation (Figure 4, C and D). To verify the effect of decorin
on AR and AR phosphorylation, we used AR antagonist, bicalutamide.
The inhibitory effects of decorin pretreatment on DHT-induced AR,
AR phosphorylation, and PSA production in LNCaP cells were similar
to that observedwith bicalutamide pretreatment (Figure 4E ).Moreover,
they were mirrored by effects on cell proliferation (Figure 4F ). Taken
together, those results indicate that, in LNCaP cells, decorin down-
regulates AR, inhibits AR nuclear translocation, depresses AR phos-
phorylation, and reduces the production of PSA.
Decorin Impacts the Cross Talking between EGFR and AR
in LNCaP Cells
Previous studies showed that besides its classic location at the nucleus,
the AR is a target at the plasma membrane for interactions with proteins
involved in growth factor signaling [37]. We examined the interaction
between EGFR and AR pathways that may be modified by decorin
in LNCaP cells. As shown in Figure 5A, EGF modestly increased AR
expression and AR phosphorylation (lane 1 vs lane 3), and this effect
was blocked by decorin (lane 3 vs lane 4). DHT also slightly activated
EGFR phosphorylation, whereas decorin blocked the stimulatory effect
of DHT (Figure 5B). This suggests that decorin may serve as a regulator
of the interaction between EGFR and AR.
To further confirm the role for decorin in directional cross talk be-
tween EGFR and AR, LNCaP cells were treated with EGFR inhibitor,
AG1478 or/and AR antagonist, bicalutamide, and then incubated with
decorin for 48 hours. Figure 5C shows that, although AG1478 alone
failed to reduce on AR expression or phosphorylation (lanes 1 and 3), it
did partially reverse the inhibitory effects of decorin on AR (lanes 2
and 4). Similarly, bicalutamide alone had little ability to reduce EGFR
phosphorylation (lanes 1 and 5) but partially reversed the inhibitory
effect of decorin on EGFR (lanes 2 and 6 ). Thus, AG1478 and bi-
calutamide pretreatment modestly reduced the respective effects of
Figure 4. Decorin inhibited AR and production of PSA in prostate of PtenP−/−mice and LNCaP cells. (A) Protein extracts from prostate of
PtenP−/− mice treated with decorin or saline (two mice in each group randomly selected) was used for Western blot analysis of AR, AR
phosphorylation, and β-actin. (B) PC3, LNCaP, and DU145 cells were treated with decorin (1 and 2 μM) or biglycan (2 μM) for 48 hours.
AR, AR phosphorylation (p-AR), and PSA proteins were measured by Western blots. Data shown are representative of two experiments
with similar results. (C) LNCaP cells were seeded on coverslips in 24-well plates at the density of 5 × 104 cells per milliliter and treated
with decorin (2 μM) or biglycan (2 μM) for 24 hours followed by 1 nM DHT for 2 hours. Cells were then incubated with anti-AR antibody
and visualized by Alexa Fluor 488 goat antirabbit immunoglobulin G and 4′,6-diamidino-2-phenylindole staining. Representative photos of
LNCaP cells were treated as indicated. Scale bar, 100 μm. Insets: High-magnification images of the areas in the white rectangles. Data
shown are representative of two experiments. (D) LNCaP cells were exposed to decorin (2 μM) or biglycan (2 μM) for 24 hours. Cytosolic
and nuclear proteins were extracted and AR was measured by Western blot analysis. Data shown are representative of three indepen-
dent experiments. (E) LNCaP cells were treated with decorin and bicalutamide (0.5 μM, pretreated for 90 minutes) for 48 hours followed
by DHT (1 nM) for 2 hours, and total proteins were isolated. AR, p-AR, and PSA were measured by Western blot assay. Data shown are
representative of two independent experiments. (F) The growth of LNCaP cells was measured by MTS assay after treatment with DHT
(1 nM), bicalutamide (0.5 μM), and decorin (2 μM) for 48 hours. Values representing the mean ± SD (n = 3) with different letters are
significantly different (P < .05).
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decorin on EGFR and AR. Finally, LNCaP cells transfected with EGFR
siRNA showed a large decrease in EGFR expression and phosphoryla-
tion by 24 hours (Figure 5D). This knockdown blocked the inhibitory
effect of decorin on AR and AR phosphorylation (Figure 5E). Taken
together, those results demonstrate that decorin suppresses the signaling
pathway from EGFR to AR.
Decorin Inhibits PI3K/Akt Phosphorylation through
Suppressions of EGFR and AR
The PI3K/Akt pathway is recognized as playing a critical regulatory
role in the cell survival/death decision [38]. To determine the involve-
ment of this pathway in the downstream signaling related to the sup-
pression of EGFR and AR by decorin, we measured Akt and PI3K
expression in cells treated with decorin. In PC3 cells, decorin inhibited
Akt phosphorylation in a dose-dependent manner (Figure 6A). In these
cells, EGF stimulated Akt phosphorylation (Figure 6B, lanes 1 and 3),
an effect that was also reduced by decorin (lanes 3 and 4 ) or AG1478
(lanes 3 and 5). In LNCaP cells, decorin decreased Akt phosphorylation
(Figure 6, C and D) and PI3K (Figure 6E ). The inhibitory effects of
decorin pretreatment onDHT-inducedAkt phosphorylation in LNCaP
cells were similar to that observed with bicalutamide (Figure 6D).
AG1478 or bicalutamide alone partially decreased the inhibitory effect
of decorin on Akt phosphorylation and PI3K but, together, almost com-
pletely blocked the effects of decorin (Figure 6,C and E). Furthermore,
the PI3K-specific inhibitor, wortmannin, also blocked the ability of
decorin to inhibit phosphorylation of Akt (Figure 6F ). These results
together indicate that decorin inhibition of PI3K/Akt depends on the
suppression of EGFR and AR.
Decorin Induces Apoptosis through Inhibition of EGFR and AR
To determine whether the observed inhibition of prostate cancer cell
growth by decorin was due in part to apoptosis induction, we measured
two biomarkers for apoptosis: caspase 3 activity and cleaved poly (ADP-
ribose) polymerase (PARP) in PC3 cells and LNCaP cells. Decorin in-
creased caspase 3 activity in both cell lines (Figure 7, A and B). In PC3
cells, EGF decreased caspase 3 activity, an effect that was blocked by
decorin and by AG1478 (Figure 7A). In LNCaP cells, DHT reduced
caspase 3 activity, an effect that was attenuated by treatment with decorin
Figure 5. Decorin impacted the cross talk between EGFR and AR in LNCaP cells. (A) LNCaP cells were treated with decorin (2 μM) for
48 hours followed by EGF (100 ng/ml) for 15 minutes. Total protein (20 μg/lane) was used for Western blot analysis of AR, p-AR, and
PSA. (B) LNCaP cells were exposed to decorin (2 μM) for 48 hours followed by DHT (1 nM) for 2 hours. Total protein was used for
measurement of EGFR and p-EGFR (Tyr 1068). (C) LNCaP cells were treated with decorin (2 μM) or AG1478 (2 μM, pretreated for 30 min-
utes) or bicalutamide (0.5 μM, pretreated for 90 minutes) for 48 hours. AR, p-AR, PSA, EGFR, and p-EGFR (Tyr 1068) were measured by
Western blot assay. (D) LNCaP cells were transfected with control siRNA or EGFR siRNA for 6 hours, then supplemented with growth
medium containing 1% FBS for 24 hours. Cells were incubated with EGF (100 ng/ml) for 15 minutes before harvest. EGFR and p-EGFR
(Tyr 1068) were measured by Western blot assay. (E) Cells were transfected with control siRNA or EGFR siRNA for 24 hours, then treated
with decorin (2 μM) for 48 hours. AR and p-AR were measured as described before. All data shown are representative of two indepen-
dent experiments.
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as well as bicalutamide (Figure 7B). The effects of decorin on apoptosis
were confirmed in Western blot assays of PARP cleavage (Figure 7,
C and D). Decorin increased cleaved PARP in PC3 and LNCaP
cells. Decorin-induced PARP cleavage was markedly reduced by the
EGFR inhibitor AG1478 in PC3 cells but only partially reduced by this
agent in LNCaP cells. The AR antagonist, bicalutamide, also decreased
decorin-induced PARP cleavage in LNCaP cells, and the combination
of AG1478 and bicalutamide completely blocked decorin-induced
PARP cleavage in these cells. These findings suggest that decorin in-
duces apoptosis through the inhibition of EGFR and AR signaling in
prostate cancer cells.
Discussion
Androgen-independent progression of prostate cancer does not seem
to involve AR loss but instead results from inappropriate activation
of AR [39,40]. This suggests that AR signaling may continue to play
a critical role in the development and progression of prostate cancer. In
addition, prostate cancer cells commonly overexpress several growth
factors and their cognate receptors, including EGFR [1,41]. Enhanced
EGFR expression is reported to be associated with high grades of pros-
tate cancer malignancies [42]. More importantly, distinct oncogenic
products are activated through the stimulation of AR or EGFR, and
interaction between growth factor signal transduction pathways and
AR signaling propels the proliferation, survival, and invasion of prostate
tumor cells, that is, through disease progression [1]. Therefore, the
integration of external signals through the modulation of EGFR and
AR activities could lead to a promising strategy for therapy in prostate
cancer. Here, we have demonstrated that systemic delivery of decorin
inhibits the progression of prostate cancer in PtenP−/− mice by inhibi-
tion of proliferation and stimulation of apoptosis. Similar effects were
observed in vitro using human prostate cancer cell lines treated with
exogenous decorin. Our study has further shown that exogenous
decorin not only suppresses EGFR and AR expression and phosphory-
lation but also impacts their cross talk. This resulted in the inhibition of
PI3K and Akt phosphorylation followed by an induction of apoptosis.
These findings emphasize the potentially cooperative effect of simul-
taneous blockade of EGFR and AR signaling, such as that achieved
by decorin, in the inhibition of prostate tumor growth.
An analysis of changing expression patterns of EGF and the EGFR
during prostate cancer progression indicates that a switch from paracrine
to autocrine EGF signaling is important to the autonomous growth of
androgen-independent cells [43]. Recent studies with human lung, liver,
Figure 6. Decorin inhibited PI3K/Akt pathway through EGFR/AR in PC3 and LNCaP cells. (A) PC3 cells were treatedwith decorin for 48 hours.
Protein extracts were used for Western blot analysis of total Akt and Akt phosphorylation (p-Akt, Ser 473). (B) PC3 cells were treated with
decorin (2 μM) or AG1478 (2 μM, pretreated for 30minutes) either alone or together for 48 hours followed by EGF (100 ng/ml) for 15minutes.
Total protein was used to measure total Akt and p-Akt. (C) LNCaP cells were incubated with decorin (0.4, 1, and 2 μM), AG1478 (2 μM,
pretreated for 30 minutes), or bicalutamide (0.5 μM, pretreated for 90 minutes) either alone or together for 48 hours. Total protein was used
for Western blot analysis of total Akt and p-Akt. (D) LNCaP cells were exposed to decorin and bicalutamide (0.5 μM, pretreated for 90 min-
utes) for 48 hours followed by 1 nMDHT for 2 hours. Total protein was used for Western blot analysis of total Akt and p-Akt. (E) LNCaP cells
were treated with decorin (2 μM), AG1478 (2 μM, pretreated for 30minutes), or bicalutamide (0.5 μM, pretreated for 90minutes) either alone
or together for 24 hours. The cells were lysed, and PI3K wasmeasured byWestern blot assay. (F) PC3 and LNCaP cells were pretreated with
PI3K inhibitor, wortmannin (50 nM), for 30 minutes followed by decorin (2 μM) treatment of 48 hours. Total Akt and p-Akt weremeasured by
Western blot assay. All data shown are representative of two independent experiments.
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colorectal, and cervical tumor cells have found that decorin can directly
interact with EGFR to regulate tumor cell growth [26,29]. Our data
show that the basal levels of EGFRpermilligram of cell protein are higher
in androgen-independent PC3 and DU145 cells than in androgen-
dependent LNCaP cells.Meanwhile, AR expression was not detectable
in PC3 and DU145 cells. Exogenous decorin inhibited the growth of
human prostate cancer cells by suppressing EGFR phosphorylation
and its downstream signaling, PI3K/Akt, and by triggering apoptosis.
Thus, decorin was a powerful regulator of androgen-independent
prostate cancer cell growth. In addition to EGFR, previous studies
have shown that decorin can also interact with other tyrosine kinase
receptors such as insulin-like growth factor 1 receptor [44,45], vascular
endothelial growth factor receptor [46], and Met receptor [47]. Those
receptors play important roles in tumor progression and are now being
regarded as targets for cancer therapy [48]. Further studies are required
to clarify a role for these receptors in the inhibitory effect of decorin in
prostate cancer.
AR classically acts at the nuclear level; however, it may also be located
at the plasma membrane, where its interacts with proteins involved in
growth factor signaling, such as Src kinase family members [49], caveo-
lin 1 [50], and PI3K [51]. AR also modulates Akt activation through a
PI3K-dependent mechanism [10,52]. PI3K/Akt activation was shown
to promote the proliferation of diverse cancer cells including those of the
prostate [38,53,54]. Our results show that in androgen-dependent
LNCaP cells, decorin inhibited AR nuclear translocation, leading to de-
creased PSA expression and a suppressed PI3K/Akt signaling pathway.
These inhibitory activities were partially reversed by the EGFR inhibi-
tor, AG1478, and by the AR antagonist, bicalutamide, and completely
abolished by the combination of bicalutamide and AG1478. Decorin
also reduced DHT- or EGF-induced effects on AR and AR phosphor-
ylation, whereas EGFR knockdown by siRNA abolished the inhibitory
effect of decorin. These results suggest that decorin inhibits AR signaling
to reduce the proliferation of androgen-dependent prostate cancer cells
through a mechanism involving an interaction between AR and EGFR.
Apparently, directional signaling from AR to EGFR was also impacted
by decorin because the AR antagonist, bicalutamide, abrogated the
effect of decorin on EGFR phosphorylation, which could be explained
by the role of AR in the regulation of EGFR endocytotic trafficking [55]
Figure 7. Decorin induced apoptosis by targeting EGFR and AR. (A) PC3 cells were treated with decorin (2 μM) or AG1478 (2 μM, pretreated
for 30 minutes) followed by EGF (100 ng/ml) for 48 hours. Caspase 3 activity was measured with the Caspase–Glo 3/7 assay. Values repre-
senting the mean ± SD (n = 3) with different letters are significantly different (P < .05). (B) LNCaP cells were treated with decorin (2 μM)
for 48 hours in the presence or absence of pretreatment with AG1478 (2 μM for 30 minutes), bicalutamide (0.5 μM for 90 minutes), or a
combination of both. Caspase 3 activity was measured with the Caspase–Glo 3/7 assay. Values representing the mean ± SD (n = 3) with
different letters are significantly different (P< .05). (C) PC3 cells were treated with decorin or the EGFR inhibitor, AG1478 (2 μM, pretreated
for 30 minutes), for 48 hours, then cleaved PARP was measured byWestern blot assay. Data shown are representative of two experiments
with similar results. (D) LNCaP cells were treated with decorin for 72 hours in the presence or absence of pretreatment with AG1478 (2 μM
for 30 minutes), bicalutamide (0.5 μM for 90 minutes), or a combination of both. Cleaved PARP was identified by Western analysis. Data
shown (C and D) are representative of two independent experiments.
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or EGFR/Erb2 heterodimer expression [56,57]. However, it remains to
be determined whether decorin can directly or sequentially bind to and
inhibit EGFR and AR or whether decorin acts indirectly to disrupt the
EGFR and AR interaction and suppress downstream mediators includ-
ing PI3K/Akt and apoptosis.
We observed that decorin inhibited the growth of androgen-
dependent and androgen-independent prostate tumor cells by sup-
pressing both EGFR- and AR-PI3K-Akt signaling. As shown in
Figure 8, in AR-negative PC3 and DU145 cells, the effects of decorin
seemed to be mediated entirely by the EGFR pathway, whereas the
AR pathway provided an additional target in AR-positive LNCaP cells.
Because of the central role of AR and EGFR in prostate cancer, new
strategies and drugs to abrogate their signaling may have important
clinical benefits. Our study provides a biologic basis for the inhibitory
effect of endogenous and exogenous decorin on prostate tumor growth.
Moreover, the clinical implications revealed by the mouse model
suggest that decorin is a promising therapeutic agent for treating pros-
tate cancer.
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